In the Research Article “Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS” by de Stefano et al.,1 the author byline should include Dr. Claire Mwape as author #14. Further, the footnote regarding APC funding for this paper should read “The Article Processing Charge was funded by the healthcare business of Merck KGaA, Darmstadt, Germany.” The market authorisation holder for MAVENCLAD stated in the introduction should read “the healthcare business of Merck KGaA, Darmstadt Germany”. Lastly, the link on page 4 for the data-sharing portal for the health care business of Merck KGaA, Darmstadt, Germany should appear as follows: emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html. The article has been replaced by a corrected version. The original version with the changes highlighted is available from a link in the corrected article. The editorial staff and authors regret these errors.
- © 2022 American Academy of Neurology
Reference
- 1.↵
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
